(2S,3R,4S,5R)-2-((R)-4-(2,4-dihydroxyphenyl)butan-2-yloxy)tetrahydro-2H-pyran-3,4,5-triol

ID: ALA3100134

PubChem CID: 72946266

Max Phase: Preclinical

Molecular Formula: C15H22O7

Molecular Weight: 314.33

Molecule Type: Small molecule

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  C[C@H](CCc1ccc(O)cc1O)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O

Standard InChI:  InChI=1S/C15H22O7/c1-8(2-3-9-4-5-10(16)6-11(9)17)22-15-14(20)13(19)12(18)7-21-15/h4-6,8,12-20H,2-3,7H2,1H3/t8-,12-,13+,14-,15+/m1/s1

Standard InChI Key:  SSQDSAFOXKKNBY-WMNSZERYSA-N

Molfile:  

     RDKit          2D

 23 24  0  0  0  0  0  0  0  0999 V2000
   30.3068   -7.1313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.5915   -7.5313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.5813   -8.3489    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.2857   -8.7674    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.0017   -8.3624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.0084   -7.5461    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.7059   -8.7770    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.6990   -9.5941    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.4032  -10.0087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.3963  -10.8259    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.1144   -9.6061    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.8892   -7.1135    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   33.8186  -10.0207    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.8070  -10.8409    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   34.5071  -11.2553    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.2207  -10.8563    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.2296  -10.0382    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.5249   -9.6191    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.8144   -9.1996    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
   34.5329   -8.8020    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   35.9233  -11.2735    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   35.9421   -9.6380    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   31.7198   -7.1441    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  5  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
  9 11  1  6
  2 12  1  0
 11 13  1  0
 13 14  1  0
 13 18  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 13 19  1  6
 18 20  1  6
 16 21  1  6
 17 22  1  1
  6 23  1  0
M  END

Associated Targets(Human)

TYR Tclin Tyrosinase (717 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

PPO2 Tyrosinase (3884 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 314.33Molecular Weight (Monoisotopic): 314.1366AlogP: -0.13#Rotatable Bonds: 5
Polar Surface Area: 119.61Molecular Species: NEUTRALHBA: 7HBD: 5
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 5#RO5 Violations (Lipinski):
CX Acidic pKa: 9.54CX Basic pKa: CX LogP: 0.61CX LogD: 0.60
Aromatic Rings: 1Heavy Atoms: 22QED Weighted: 0.51Np Likeness Score: 1.78

References

1. Iwadate T, Kashiwakura Y, Masuoka N, Yamada Y, Nihei K..  (2014)  Chemical synthesis and tyrosinase inhibitory activity of rhododendrol glycosides.,  24  (1): [PMID:24332496] [10.1016/j.bmcl.2013.11.063]
2. Iwadate T, Nihei K..  (2015)  Rhododendrol glycosides as stereospecific tyrosinase inhibitors.,  23  (20): [PMID:26386819] [10.1016/j.bmc.2015.09.014]

Source